2.Bridging the US and China together to conquer cancer: report of the 4th annual meeting of the US Chinese Anti-Cancer Association (USCACA).
Chinese Journal of Cancer 2012;31(7):315-318
A global collaborative effort is pivotal to conquer cancer. Themed "Emerging role of China in global clinical development of novel anti-cancer drugs", the US Chinese Anti-Cancer Association (USCACA) held its 4th annual meeting in Chicago on June 2, 2012, in conjunction with the American Society of Clinical Oncology (ASCO) annual meeting to further bridge the US and China together to outsmart cancer. Although a young organization, USCACA has made significant contributions to this goal in the 3 years since its inception through extensive collaboration with academic organizations, the pharmaceutical industry, and governmental agencies. USCACA has engaged various stakeholders in developing translational and personalized medical strategies to facilitate new anti-cancer drug development and clinical trials in China. USCACA has initiated and implemented the USCACA-National Foundation for Cancer Research (NFCR) scholarship to encourage overseas returnees to continue cancer research in China. USCACA announced the Hengrui-USCACA scholarship to fund clinical trial staff from China to conduct the observation of early oncologic clinical trials in the US. During the annual meeting, distinguished panelists and the audience discussed the following critical topics:(1) oncologic translational research and early development capabilities in China;(2) novel chemical entity development and partnership with Chinese companies; and (3) Chinese participation in global anti-cancer drug development. USCACA will continue to promote collaborations among cancer researchers and clinicians in the US and China by engaging in more frequent communications and joint efforts across fields, disciplines, and countries, diligently working together toward curing and eliminating cancers.
Chicago
;
China
;
International Cooperation
;
Medical Oncology
;
Societies, Medical
;
United States
3.Biological functions of decorin in cancer.
Chinese Journal of Cancer 2013;32(5):266-269
Decorin is a member of the extracellular matrix small leucine-rich proteoglycans family that exists and functions in stromal and epithelial cells. Accumulating evidence suggests that decorin affects the biology of various types of cancer by directly or indirectly targeting the signaling molecules involved in cell growth, survival, metastasis, and angiogenesis. More recent studies show that decorin plays important roles during tumor development and progression and is a potential cancer therapeutic agent. In this article, we summarize recent studies of decorin in cancer and discuss decorin's therapeutic and prognostic value.
Biomarkers, Tumor
;
metabolism
;
Cell Proliferation
;
Decorin
;
metabolism
;
Extracellular Matrix
;
metabolism
;
Humans
;
Neoplasm Metastasis
;
Neoplasms
;
metabolism
;
pathology
;
Neovascularization, Pathologic
;
Prognosis
4.The USCACA hosted symposiums at the 7th CACA annual meeting and the 15th CSCO annual meeting in Beijing.
Michael SHI ; Wancai YANG ; Pascal QIAN ; Li YAN
Chinese Journal of Cancer 2012;31(11):505-506
In September 2012, the US Chinese Anti-Cancer Association (USCACA) hosted two symposiums in Beijing. The USCACA hosted the first joint session at the 7th annual meetings of the Chinese Anti-Cancer Association (CACA), themed on "Collaboration between the US and China in Cancer Research." Six experts from the United States and China presented their latest work on basic and translational cancer research. During this symposium, 5 young Chinese scholars, returnees after their training in the United States, were honored the"AFCR-USCACA Scholarships Award." The USCACA hosted a second symposium during the 15th annual meeting of the Chinese Society of Clinical Oncology (CSCO), focused on the "US-China Collaboration in Cancer Drug Clinical Development." An international delegation of oncology experts presented the innovative clinical trial strategies and discussed the biomarkers for cancer early detection and clinical trials, targeted therapy, and new drug development. The Oncology Drug Clinical Development and Safety Evaluation Committee was also launched to promote an innovative environment and to provide a collaborative platform for anti-cancer drug development in China.
Awards and Prizes
;
China
;
Drug Discovery
;
International Cooperation
;
Medical Oncology
;
Societies, Medical
;
United States
5.Mouse models of colorectal cancer.
Yunguang TONG ; Wancai YANG ; H Phillip KOEFFLER
Chinese Journal of Cancer 2011;30(7):450-462
Colorectal cancer is one of the most common malignancies in the world. Many mouse models have been developed to evaluate features of colorectal cancer in humans. These can be grouped into genetically-engineered, chemically-induced, and inoculated models. However, none recapitulates all of the characteristics of human colorectal cancer. It is critical to use a specific mouse model to address a particular research question. Here, we review commonly used mouse models for human colorectal cancer.
Adenomatous Polyposis Coli
;
genetics
;
pathology
;
Animals
;
Colorectal Neoplasms
;
chemically induced
;
etiology
;
genetics
;
pathology
;
Colorectal Neoplasms, Hereditary Nonpolyposis
;
genetics
;
pathology
;
Disease Models, Animal
;
Genetic Engineering
;
Humans
;
Inflammation
;
complications
;
Mice
;
Mice, Transgenic
;
Neoplasm Metastasis